Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration.

Under the arrangement, prices for GLP-1 drugs—used both for diabetes and obesity—will be slashed for Medicare and Medicaid beneficiaries. The prices of Ozempic and Wegovy will fall from $1,000 and $1,

Telehealth for Medicare started during the pandemic and became popular quickly. But the shutdown put an abrupt halt to payments for the service.

Medicare cover GLP-1s under a Trump-negotiated pricing plan starting in 2026, lowering costs for key obesity and diabetes drugs.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.

As millions of Americans prepare to review their health coverage this fall, confusion continues to swirl around one of the most misunderstood parts of the Medicare system - Medigap

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) to set a negotiated price for

Seniors could soon pay just $50 a month for Ozempic and other drugs used for weight loss under a new Trump plan to cut prescription costs.

The Better Business Bureau is warning Middle Georgia residents about scam calls and texts pretending to help with Medicare or Healthcare.gov coverage during open enrollment. Officials say the scams target personal information and could lead to identity theft.